HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr

Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years

Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr

The pharma market is showing encouraging signs of improvement, positioning us well for future growth

Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut

Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care

Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore

Daiichi Sankyo and Merck enter into global agreement for MK-6070

To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights

Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP

Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024